The complaint alleges that ADMA Biologics violated the Securities Exchange Act of 1934 by disseminating false and misleading information to the market. Specifically, the litigation claims the company failed to disclose a significant related-party transaction and engaged in channel stuffing—the practice of inflating sales figures by shipping excess inventory to distributors to simulate organic demand.
In section Releases
Investors Target ADMA Biologics in Securities Fraud Class Action
A federal class action lawsuit now challenges ADMA Biologics, accusing the company of inflating its financial health through deceptive trade practices between August 9, 2024, and March 25, 2026. The DJS Law Group is currently organizing shareholders who incurred losses during this period to seek potential legal recovery.
Shareholders who purchased ADMA stock during the specified window have until August 10, 2026, to file for lead plaintiff status. Participation in the lawsuit does not mandate a formal lead role, though the DJS Law Group is actively vetting claimants to build its case. The firm, led by David J. Schwartz, specializes in securities litigation and is currently inviting affected investors to submit their documentation regarding the alleged market manipulation.
Comments (0)
No comments yet. Be the first!